COMMONWEALTH OF KENTUCKY CABINET FOR HEALTH AND FAMILY SERVICES DEPARTMENT FOR MEDICAID SERVICES

PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING

NOTE: This special called meeting will be held virtually via Zoom webinar.

Thursday, May 20, 2021 1:00 P.M. to 4:00 P.M. (Eastern)

Access Information

Smartphone/Web	Dial-In
https://magellanhealth.zoom.us/s/97862762833	+1 312 626 6799 (US Toll) OR
Webinar ID: 978 6276 2833	+1 646 558 8656 (US Toll)
Password: 517539	Webinar ID: 978 6276 2833
	Passcode: 517539

AGENDA

- I. Call to Order and Welcome
- II. Executive Session (upon request)
- III. Old Business
 - a. Approval of Meeting Minutes
- **IV.** New Business
 - a. New Products to Market to be reviewed as single products:
 - i. Vocabria (HIV/AIDS)
 - ii. Verquvo® (Vasodilators, Coronary)

I. Therapeutic Classes with Recommended Changes

- a. Analgesics, Narcotics, Long
- b. Analgesics, Narcotics
 - i. Short-Acting
 - ii. Narcotic Agonist/Antagonists
 - iii. Narcotics: Fentanyl Buccal Products
- c. Androgenic Agents
- d. Antihyperuricemics
- e. Antimigraine Agents, Other (Antimigraine Agents, CGRP Inhibitors)
- f. Antimigraine Agents, Triptans (Antimigraine Agents, 5-HT1 Receptor Agonists
- g. Bone Resorption Suppression and Related Agents
- h. Erythropoiesis Stimulating Proteins
- i. Hypoglycemics, Alpha-Glucosidase Inhibitors (Diabetes: Alpha-Glucosidase Inhibitors)
- j. Hypoglycemics, Insulin and Related Agents (Diabetes: Insulins and Related Agents)
- k. Hypoglycemics, SGLT2 Inhibitors (Diabetes: SGLT2 Inhibitors)
- 1. Neuropathic Pain
- m. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- n. Phosphate Binders

V. Consent Agenda

a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

Colony Stimulating Factors	Hypoglycemics, Sulfonylureas (Diabetes: Sulfonylureas)
Glucagon Agents	Hypoglycemics, Thiazolidinediones (TZD) (Diabetes: Thiazolidinediones)
Glucocorticoids, Oral (Oral Steroids)	Pancreatic Enzymes
Growth Hormone	Progestins for Cachexia
Hypoglycemics, Incretin Mimetics/Enhancers Diabetes: DPP4 Inhibitors Diabetes: GLP-1 Receptor Agonists	Skeletal Muscle Relaxants
Hypoglycemics, Meglitinides (Diabetes: Meglitinides)	Thrombopoiesis Stimulating Proteins (Thrombopoiesis Stimulating Agents)
Hypoglycemics, Metformins (Diabetes: Metformins)	

V. Adjournment

- a. Schedule of Upcoming Meetings
 - i. July 15, 2021
 - ii. September 16, 2021
 - iii. November 18, 2021
 - iv. **January 20, 2022**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria please go to https://kyportal.magellanmedicaid.com/provider/public/home.xhtml.

PUBLIC SPEAKERS: If you would like to speak during the public session please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml.